Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Dose-Escalation and Cohort-Expansion Study of the Safety, Tolerability, and Efficacy of a Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor (Galunisertib) Administered in Combination With the Anti-PD-L1 Antibody Durvalumab (MEDI4736) in Recurrent or Refractory Metastatic Pancreatic Cancer

NCT02734160 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT02734160
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02734160 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Dose-Escalation and Cohort-Expansion Study of the Safety, Tolerability, and Efficacy of a Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor (Galunisertib) Administered in Combination With the Anti-PD-L1 Antibody Durvalumab (MEDI4736) in Recurrent or Refractory Metastatic Pancreatic Cancer
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
June 15, 2016
Completion date
April 17, 2019
Enrollment
37 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic cancer